Sector News

Pfizer makes moves to offload Hospira's pumps and devices business

May 3, 2016
Life sciences

Pfizer has begun taking offers on Hospira’s pumps and devices business, after considering offloading it for some time. A sale would free Pfizer of an acquisition that falls outside the scope of its traditional drug business.

Med tech companies Smiths Group and Fresenius put in bids for the unit, which Pfizer picked up last year through its $15 billion deal for Hospira. Private equity firm Pamplona Capital made a second-round bid for the business, Bloomberg reports, although final bids for the unit aren’t due until the end of May.

Pfizer has said that it could reap about $2 billion from a sale of Hospira’s devices business. Representatives from Pfizer, Germany’s Fresenius and London-based Smiths Group declined to comment to the news outlet.

Pfizer snatched up Hospira in order to get its hands on the company’s biosimilars and generic injectables. Hospira’s pumps and devices unit doesn’t fit in with the rest of Pfizer’s established products business, and selling the business would create a more pure-play drugs unit that’s ripe for a sale, IPO or spinoff.

More changes could also be on the horizon for Pfizer after its $160 billion deal with Allergan ($AGN) fell through last month. The company is going to decide by the end of this year whether it should break into two separate businesses, its original timeline for the breakup, Pfizer CEO Ian Read said at the time.

And meanwhile, the drug giant will continue to scout out deals and explore “other shareholder friendly capital allocation opportunities,” he said in a statement.

By Emily Wasserman

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.